Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 10;13:34. doi: 10.1186/s13045-020-00867-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Effect of imatinib treatment on IL3-independent growth and leukemogenesis of Abi1-deficient p185^Bcr-Abl cells. a. Imatinib induces dose-dependent cell death in control p185^Bcr-Abl cells (p185 Cas9) and Abi1-deficient p185^Bcr-Abl cells (p185 KO2.3 and p185 KO6.2). The p185 Cas9, p185 KO2.3, and p185 KO6.2 cells grown in IL3-free growth medium were treated with imatinib at 0.31, 0.63, 1.25, 2.5, 5, and 10 μM, as indicated, for 48 h, cell viability was determined by trypan blue exclusion assay and represented as average +/- SD of triplicate wells. b. Imatinib-induced cell death in parental and imatinib-tolerant (IM^r) p185 Cas9, p185 KO2.3, and p185 KO6.2 cells. The p185 Cas9, p185 KO2.3, and p185 KO6.2 cells are selected without (parental) or with 1.25 μM imatinib (IM^r) for six weeks. The cells were then treated with 1.25 μM imatinib for 72 h in IL3-free growth medium. The cell viability was determined by trypan blue exclusion assay and represented as mean +/- SD of triplicate wells. c. Effect of imatinib treatment on the survival of syngeneic mice injected with the control p185^Bcr-Abl (p185 Ctrl) and imatinib-tolerant p185^Bcr-Abl (p185 IMr) cells. The Balb/C mice were injected through tail vein with 1X10⁶ p185 Ctrl or p185 IMr cells, as indicated. Ten days post-injection the mice were administered intraperitoneally once a day with either saline as control or imatinib (IM, 100 mg/Kg body weight), as indicated, for 5 consecutive days. Survival of the mice were monitored and expressed as the percentage of survival. d. The Abi1 deficient p185^Bcr-Abl cells tolerant to imatinib failed to develop leukemia in syngeneic mice. The Balb/C mice were injected through tail vein with 1X10⁶ imatinib-tolerant p185^Bcr-Abl control (p185 Ctrl IMr) cells as well as imatinib-tolerant p185 KO2.3 and p185 KO6.2 cells (p185 KO2.3 IMr and p185 KO6.2 IMr). Ten days post-injection the mice injected with p185 Ctrl IMr cells were administered intraperitoneally once a day with imatinib (IM, 100 mg/Kg body weight) for 5 consecutive days. Survival of the mice were monitored and represented as the percentage of survival